| Albert Pesigan, OT | |
|
809 Chalan Pasaheru Unit 2, Tamuning, GU 96913-4132 | |
| (671) 647-5355 | |
| (671) 647-5358 |
| Full Name | Albert Pesigan |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapist |
| Location | 809 Chalan Pasaheru Unit 2, Tamuning, Guam |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982064721 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT-27 (Guam) | Primary |
| Provider Name | Gurusamy Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1942277967 PECOS PAC ID: 2567435563 Enrollment ID: O20141031002080 |
News Archive
The use of acupuncture to treat pain dates back to the earliest recorded history in China. Despite centuries of acupuncture, it's still not clear why this method of applying and stimulating tiny needles at certain points on the body can relieve pain.
Nearly 28 percent of California's children have untreated tooth decay, according to the 2006 California Smile Survey, Mommy It Hurts to Chew. Families with low incomes and people with complex medical conditions face considerable barriers to obtaining dental care and have significantly worse oral health than other segments of the population.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
New research on the types of bacteria living in babies' noses could offer clues as to why some recover quickly from their first cough or cold, while others suffer for longer.
› Verified 5 days ago
| Provider Name | Guam Healthcare Development Incorporated |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1326447939 PECOS PAC ID: 9234351776 Enrollment ID: O20150326000266 |
News Archive
The use of acupuncture to treat pain dates back to the earliest recorded history in China. Despite centuries of acupuncture, it's still not clear why this method of applying and stimulating tiny needles at certain points on the body can relieve pain.
Nearly 28 percent of California's children have untreated tooth decay, according to the 2006 California Smile Survey, Mommy It Hurts to Chew. Families with low incomes and people with complex medical conditions face considerable barriers to obtaining dental care and have significantly worse oral health than other segments of the population.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
New research on the types of bacteria living in babies' noses could offer clues as to why some recover quickly from their first cough or cold, while others suffer for longer.
› Verified 5 days ago
| Provider Name | Gurusamy Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1942277967 PECOS PAC ID: 2567435563 Enrollment ID: O20161020001980 |
News Archive
The use of acupuncture to treat pain dates back to the earliest recorded history in China. Despite centuries of acupuncture, it's still not clear why this method of applying and stimulating tiny needles at certain points on the body can relieve pain.
Nearly 28 percent of California's children have untreated tooth decay, according to the 2006 California Smile Survey, Mommy It Hurts to Chew. Families with low incomes and people with complex medical conditions face considerable barriers to obtaining dental care and have significantly worse oral health than other segments of the population.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
New research on the types of bacteria living in babies' noses could offer clues as to why some recover quickly from their first cough or cold, while others suffer for longer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Albert Pesigan, OT Po Box 8838, Tamuning, GU 96931-8838 Ph: (671) 647-5355 | Albert Pesigan, OT 809 Chalan Pasaheru Unit 2, Tamuning, GU 96913-4132 Ph: (671) 647-5355 |
News Archive
The use of acupuncture to treat pain dates back to the earliest recorded history in China. Despite centuries of acupuncture, it's still not clear why this method of applying and stimulating tiny needles at certain points on the body can relieve pain.
Nearly 28 percent of California's children have untreated tooth decay, according to the 2006 California Smile Survey, Mommy It Hurts to Chew. Families with low incomes and people with complex medical conditions face considerable barriers to obtaining dental care and have significantly worse oral health than other segments of the population.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.
New research on the types of bacteria living in babies' noses could offer clues as to why some recover quickly from their first cough or cold, while others suffer for longer.
› Verified 5 days ago
Rosalind Taitingfong, O.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 809 Chalan Pasaheru Unit 2, Tamuning, GU 96913 Phone: 671-647-5355 Fax: 671-647-5358 |